我們已在上線！ 進一步了解
IMGN圖示

Immunogen Inc
IMGN

已下市

IMGN已於2024年2月9日下市。

返回排名列表
 

關於： Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.

員工： 277

醫療保健 藥品製造商－一般

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%
正面
Zacks Investment Research
2 年前
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
正面
Zacks Investment Research
2 年前
ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?
ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
正面
InvestorPlace
2 年前
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
As 2023 wrapped up, Russell 2000 stocks, mirroring the dynamics of small-to-mid-cap companies, showed resilience, outperforming their initial stance. The iShares Russell 2000 ETF (NYSEARCA: IWM ), a key barometer for these stocks, boasts over $60 billion in assets and a robust daily trading volume surpassing 40 million, setting an impressive stage for these agile market players.
中性
Business Wire
2 年前
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
正面
Zacks Investment Research
2 年前
How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry
ImmunoGen (IMGN) has seen solid earnings estimate revision activity over the past two month, and belongs to a strong industry as well.
正面
CNBC
2 年前
Cramer names biopharma companies to watch as industry mergers start to pile up
CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.
正面
Zacks Investment Research
2 年前
All You Need to Know About ImmunoGen (IMGN) Rating Upgrade to Strong Buy
ImmunoGen (IMGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
正面
Zacks Investment Research
2 年前
Best Momentum Stocks to Buy for January 4th
IMGN and GTLB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 4, 2024.
正面
Zacks Investment Research
2 年前
New Strong Buy Stocks for January 4th
IMGN, GTLB, FNWD, BL and TMHC have been added to the Zacks Rank #1 (Strong Buy) List on January 4, 2024.
中性
Business Wire
2 年前
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
查看新聞排名
價格圖表採用Lightweight Charts™實作